<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 23: Summary of Virologic Failures<sup>a</sup> at Week 96 in Study AI424-089: Comparison of Ritonavir Boosted REYATAZ vs. Unboosted REYATAZ: Randomized Patients</caption>
<col width="50%"></col>
<col width="25%"></col>
<col width="25%"></col>
<thead>
<tr>
<th align="left" rowspan="2" stylecode="Botrule Toprule " valign="top">
<content stylecode="bold"> </content>
</th>
<th align="center" stylecode="Toprule " valign="top">
<content stylecode="bold">REYATAZ 300 mg<br/>+</content>
<br/>
<content stylecode="bold">ritonavir 100 mg </content>
</th>
<th align="center" stylecode="Toprule " valign="top">
<content stylecode="bold">REYATAZ 400 mg</content>
</th>
</tr>
<tr>
<th align="center" stylecode="Botrule " valign="top">
<content stylecode="bold">(n=95)</content>
</th>
<th align="center" stylecode="Botrule " valign="top">
<content stylecode="bold">(n=105) </content>
</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="3" stylecode="Botrule" valign="top">
<sup>a</sup> Virologic failure includes patients who were never suppressed through Week 96 and on study at Week 96, had virologic rebound or discontinued due to insufficient viral load response.<br/>
<sup>b</sup> Percentage of Virologic Failure Isolates with genotypic and phenotypic data.<br/>
<sup>c</sup> Mixture of I50I/L emerged in 2 other ATV 400 mg-treated patients. Neither isolate was phenotypically resistant to ATV.</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Toprule ">
<paragraph>Virologic Failure (≥50 copies/mL) at Week 96  </paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>15 (16%)</paragraph>
</td>
<td align="center" stylecode="Toprule ">
<paragraph>34 (32%)</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Virologic Failure with Genotypes and Phenotypes Data</paragraph>
</td>
<td align="center">
<paragraph>5</paragraph>
</td>
<td align="center">
<paragraph>17</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Virologic Failure Isolates with ATV-resistance at Week 96 </paragraph>
</td>
<td align="center">
<paragraph>0/5 (0%)<sup>b</sup>
</paragraph>
</td>
<td align="center">
<paragraph>4/17 (24%)<sup>b</sup>
</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>Virologic Failure Isolates with I50L Emergence at Week 96<sup>c</sup>
</paragraph>
</td>
<td align="center">
<paragraph>0/5 (0%)<sup>b</sup>
</paragraph>
</td>
<td align="center">
<paragraph>2/17 (12%)<sup>b</sup>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Botrule ">
<paragraph>Virologic Failure Isolates with Lamivudine Resistance at Week 96</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>2/5 (40%)<sup>b</sup>
</paragraph>
</td>
<td align="center" stylecode="Botrule ">
<paragraph>11/17 (65%)<sup>b</sup>
</paragraph>
</td>
</tr>
</tbody>
</table>